Bilateral Single-Electrode VO Combined With STN-DBS for Treating Meige Syndrome

Condition(s) studied

Investigational drug(s) / intervention(s)

deep brain stimulation: bilateral single-electrode VO combined with STN target implantation

Study summary

Meige syndrome is a rare and debilitating movement disorder characterized by blepharospasm, oromandibular dystonia, and cervical muscle contractions, often refractory to pharmacological therapies. Deep brain stimulation (DBS), initially developed to treat essential tremor and Parkinson's disease, has been explored in recent years as a potential treatment for various dystonias, including Meige's syndrome. This clinical study aims to evaluate the safety and efficacy of bilateral single-electrode ventralis oralis (VO) nucleus stimulation combined with subthalamic nucleus deep brain stimulation (STN-DBS) in patients with Meige syndrome.

Eligibility

Primary outcome measure(s)

• Improvement of primary symptoms — 1 year after stimulation
  Scale title: Burke-Fahn-Marsden Dystonia Rating Scale Section I: Motor subscale (0-120) Section II: Disability scale (0-30) Higher scores: Indicate worse outcomes (more severe dystonia symptoms).

Trial sites (1)

More Huashan Hospital trials in China